The FDA has approved thalidomide (Thalomid, Celgene Corp, Warren, NJ), with unprecedented restrictions on distribution, for the treatment of one form of leprosy—either for acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) or as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. It is not indicated as monotherapy for ENL treatment in the presence of moderate to severe neuritis.
Nightingale SL. Thalidomide Approved for Erythema Nodosum Leprosum. JAMA. 1998;280(10):872. doi:10.1001/jama.280.10.872
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: